Evidence map›Paper›PMID 40594261›Full record

SynthesisScientific reports2025

Glucose homeostasis and cognitive functions in schizophrenia: a systematic review and meta-analysis.

Alexander Kancsev, Eszter Éva Virág-Tulassay, Marie Anne Engh, Szilvia Kiss-Dala, András Attila Horváth, Péter Hegyi, Szabolcs Kéri

Abstract readSystematic ReviewMeta-Analysis
In one paragraph

Synthesis in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alexander KancsevCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Eszter Éva Virág-TulassayCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Marie Anne EnghCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Szilvia Kiss-DalaCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
András Attila HorváthCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Péter HegyiCentre for Translational Medicine, Semmelweis University, Budapest, Hungary.
Szabolcs KériCentre for Translational Medicine, Semmelweis University, Budapest, Hungary. keri.szabolcs@unithe.hu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Schizophrenia is a lifelong mental disorder associated with cognitive dysfunctions. Comorbid metabolic dysregulations, such as diabetes and insulin resistance, may further deteriorate cognitive functions. It is therefore essential to investigate the effects of these metabolic disturbances on cognition in this population. A systematic review and meta-analysis following PRISMA guidelines was conducted using data from five databases: Medline, Embase, CENTRAL, Scopus, and Web of science. Of the 26 studies included, 9 were meta-analyzed with random effects model. The search was completed on November 23, 2023 and updated on April 2, 2025. We examined the cognitive functions of schizophrenia patients with and without diabetes or insulin resistance, using standardized mean differences (SMD) or mean differences (MD) as outcomes. The review section provides an overview of the literature on the relationship between glucose homeostasis and cognitive functions. The risk of bias was assessed using the QUIPS tool. There is a clear trend suggesting that diabetes exacerbates cognitive dysfunction in schizophrenia (global cognition: SMD=-0.26; P = 0.1087; 95% CI, -0.59 to 0.08), particularly in domains such as reasoning (SMD=-0.40; P = 0.0109, 95% CI -0.58 to -0.22) and processing speed (SMD=-0.43; P = 0.0005, 95% CI -0.52 to -0.35). Conflicting results were observed in studies on insulin resistance (global cognition: SMD=-0.12; P = 0.5890; 95% CI -0.91 to 0.68). Our findings suggest that glucose metabolism dysregulations might worsen cognitive dysfunctions in schizophrenia. However, further research is needed with larger samples and less heterogeneous studies to investigate if the effect is statistically significant. Addressing these metabolic issues could help improve cognitive and functional outcomes in schizophrenia patients.

Indexed as

CognitionCognitive DysfunctionGlucoseHomeostasisSchizophreniaDiabetes MellitusHumansInsulin ResistanceGlucose

Identifiers

PMID40594261
PMCPMC12215534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.